Twist inks collaboration deal with Adicet Bio

By The Science Advisory Board staff writers

September 13, 2021 -- Twist Bioscience and Adicet Bio will collaborate on the discovery and development of gamma delta T-cell cancer therapies.

The companies will develop immune cells with human chimeric antigen receptors and T-cell receptors aimed at disease-specific cell surface antigens, Twist said. Twist will contribute its proprietary single-chain fragment variable and VHH nanobody technologies from its library, which will support Adicet's discovery of new chimeric antigen receptors to generate novel gamma delta CAR T-cell products.

Adicet will pay Twist an upfront licensing fee as well as clinical and regulatory milestone payments and royalties.

Boehringer, Twist to collaborate on antibody discovery
Boehringer Ingelheim and Twist Bioscience have entered a research collaboration to discover therapeutic antibodies against multiple targets.
Twist reports revenue increases for Q3
Twist Bioscience reported revenue increases for the third quarter of fiscal 2021, which ended June 30.
Twist incorporates Molcure AI into antibody discovery efforts
Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.
Twist acquires iGenomX for $35M
Twist Bioscience has acquired next-generation sequencing library preparation developer iGenomX for $35 million. The deal gives Twist a leg up in...
Twist, Regeneron partner on genetics NGS panel
Twist Bioscience is collaborating with Regeneron subsidiary Regeneron Genetics Center to launch a custom next-generation sequencing (NGS) population genetics...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter